Antihypertensive effect of captopril, canrenoate potassium, and atenolol. Relations with red blood cell sodium transport and renin. 1988

E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
Istituto di Scienze Mediche, Scuola di Specializzazione in Nefrologia, University of Milano, Italy.

We compared the antihypertensive efficacy of atenolol (100 mg/d), canrenoate potassium (200 mg/d), and captopril (75 mg/d) in 30 essential hypertensives. The three drugs were administered in a randomized change-over sequence for four-months each. The main variables associated with blood pressure regulation were measured in the basal condition and at the end of each treatment period. The erythrocyte Na transport systems were measured only in the basal condition and at the end of the first treatment period. The average blood pressure reduction was similar for each drug. Mean blood pressure levels after captopril correlated positively with those after atenolol in the individual patients (P less than 0.0001); mean blood pressure levels after canrenoate potassium, on the contrary, did not correlate with those after the other two drugs. Captopril and canrenoate potassium treatment reduced intraerythrocyte Na content (P less than 0.02), canrenoate potassium increased Na-K pump (P0.05), atenolol did not change any erythrocyte membrane Na transport parameters. The ouabain-resistant Na transport systems were not modified by any drug. The patients were divided in three groups according to their antihypertensive response: nonresponders (six patients), canrenoate potassium responders (nine patients) and captopril-atenolol responders (15 patients, equally responsive to both drugs). Nonresponders had the lowest basal Na pump (P less than 0.02). Canrenoate potassium responders had higher basal Na-K cotransport than captopril-atenolol responders (P less than 0.02). Atenolol-captopril responders had the highest basal plasma renin activity (PRA, P less than 0.02). The blood pressure reduction after atenolol correlated with the induced fall in PRA (P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011245 Pregnadienes Pregnane derivatives containing two double bonds anywhere within the ring structures.
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002191 Canrenoic Acid A synthetic pregnadiene derivative with anti-aldosterone activity. Canrenoate Potassium,Potassium Canrenoate,17-Hydroxy-3-Oxo-17alpha-Pregna-4,6-Diene-21-Carboxylic Acid,Kalium-Can.-Ratiopharm,SC-14266,Soldactone,Soludactone,Spiroctan,17 Hydroxy 3 Oxo 17alpha Pregna 4,6 Diene 21 Carboxylic Acid,Acid, 17-Hydroxy-3-Oxo-17alpha-Pregna-4,6-Diene-21-Carboxylic,Acid, Canrenoic,Canrenoate, Potassium,Kalium Can. Ratiopharm,SC 14266,SC14266
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D004910 Erythrocyte Membrane The semi-permeable outer structure of a red blood cell. It is known as a red cell 'ghost' after HEMOLYSIS. Erythrocyte Ghost,Red Cell Cytoskeleton,Red Cell Ghost,Erythrocyte Cytoskeleton,Cytoskeleton, Erythrocyte,Cytoskeleton, Red Cell,Erythrocyte Cytoskeletons,Erythrocyte Ghosts,Erythrocyte Membranes,Ghost, Erythrocyte,Ghost, Red Cell,Membrane, Erythrocyte,Red Cell Cytoskeletons,Red Cell Ghosts
D005260 Female Females

Related Publications

E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
April 1993, American journal of hypertension,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
January 1985, European journal of clinical pharmacology,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
January 1979, The Journal of general physiology,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
January 1986, Nephron,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
September 1981, Clinical pharmacology and therapeutics,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
June 1995, American journal of hypertension,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
May 1974, Biochimica et biophysica acta,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
November 1966, The American journal of medicine,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
September 2016, Clinical physiology and functional imaging,
E Niutta, and D Cusi, and R Colombo, and G Tripodi, and M Pellizzoni, and P Pati, and B Cesana, and E Alberghini, and C Barlassina, and G Bianchi
June 1991, Journal of human hypertension,
Copied contents to your clipboard!